Recurrent Osteosarcoma Completed Phase 2 Trials for Glembatumumab vedotin (DB05996)

Also known as: Osteosarcoma recurrent / Osteogenic sarcoma recurrent

IndicationStatusPhase
DBCOND0028757 (Recurrent Osteosarcoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02487979Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory OsteosarcomaTreatment